FUDR Disease Interactions

An inherited deficiency of dihydropyrimidine can alter the clearance of 5- FU and result in severe toxicity such as stomatitis, diarrhea, neutropenia and neurotoxicity. When administered as a continuous intra-arterial infusion, floxuridine (FUDR) is metabolized to FDUMP. However, with rapid intra-arterial injection, FUDR is metabolized to 5-FU. 5-FU requires metabolized to an inactive form by dihydropyrimidine dehydrogenase. FUDR should not be administered by rapid intra-arterial infusion to patients with dihydropyrimidine deficiency.

The use of floxuridine (FUDR) is contraindicated in patients with potentially serious infectious diseases. FUDR can induce myelosuppression. All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during therapy with FUDR. Close clinical monitoring of hematopoietic function is recommended.

Floxuridine therapy is contraindicated for patients in a poor nutritional state.

The use of floxuridine (FUDR) is contraindicated in patients with bone marrow suppression. FUDR induces myelosuppression at recommended dosages. Therapy with FUDR should be administered cautiously in patients who have had prior high-dose pelvic irradiation or alkylating agents or who have widespread metastatic tumor involvement of the bone marrow. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding. Close clinical monitoring of hematopoietic function is recommended and therapy should be withheld if platelet counts falls below 100,000/mm3 and/or white blood cell (WBC) counts falls below 3500/mm3 or a rapid fall in WBC is noted.

Floxuridine induces stomatitis within the gastrointestinal tract. Therapy with floxuridine should be administered with extreme caution in patients with peptic ulcer disease and ulcerative colitis.

Floxuridine (FUDR) induces myelosuppression. Therapy with FUDR should be administered cautiously in patients with bleeding tendencies. Therapy with FUDR should be promptly discontinued following bleeding from any sight. Patients should be instructed to immediately report any signs or symptoms suggesting bleeding such as petechiae, purpura, hematuria, or melena. Close clinical monitoring of hematopoietic function is recommended. Therapy with FUDR should be withheld if platelet counts falls below 100,000/mm3.